An interventional study of "Venarus®" (diosmin and hesperidin) and Endovenous laser ablation (EVLA) with miniphlebectomy in Varicose Veins of Lower Limb, Varix and Vascular Diseases, sponsored by Ryazan State Medical University. Active, not recruiting at 1 site in Russia. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by Ryazan State Medical University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study is aimed at assessing the dynamics of changes in biochemical markers of venous wall remodeling (type 1 plasminogen activation inhibitor (PAI-1), fibronectin (fibronectin, FN), vimentin (vimentin, VM), von Willebrand factor (vWF), PECAM-1 (CD31) ) in patients with C2s-C3s varicose veins compared with healthy volunteers while taking Venarus® (diosmin in combination with hesperidin).
The study will include 80 patients with varicose veins of the lower extremities, CEAP (CEAP classification stands for Clinical (C), Etiological (E), Anatomical (A), and Pathophysiological (P)) clinical class C2s-C3s and 20 healthy volunteers of similar age, gender, and ethnicity (100 patients altogether). The study participants will be divided into five groups: Group A: 20 patients with varicose veins who will be treated conservatively - receive the drug "Venarus®" (diosmin in combination with hesperidin) at a dosage of 1000 mg once daily for 6 months; Group B: 20 patients with varicose veins C2s-C3s who are not prescribed conservative therapy with venoactive drugs and will not undergo invasive treatment; Group C: 20 patients with varicose veins who will undergo invasive treatment (endovenous laser ablation with miniphlebectomy), followed by Venarus at a dosage of 1000 mg once daily for 6 months; Group D: 20 patients with varicose veins who will undergo invasive treatment (endovenous laser ablation with miniphlebectomy), after which no venoactive drugs will be prescribed. Group E: 20 healthy volunteers without clinical and ultrasound signs of varicose veins.
All subjects in groups A, B, C, and D will receive elastic compression.
226 studies on the registry are indexed under Varicose Veins; 30 are open to participants now.
This study's enrollment of 100 is close to the median of 101 across 154 interventional studies indexed under Varicose Veins.
Browse Varicose Veins studies →Ryazan State Medical University is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
20 patients with varicose veins who will be treated conservatively - receive the drug "Venarus®" (diosmin in combination with hesperidin) at a dosage of 1000 mg once daily for 6 months along with elastic compression
Drug: "Venarus®" (diosmin and hesperidin) · Other: Elastic compression · Other: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
20 patients with varicose veins C2s-C3s who are not prescribed conservative therapy with a venoactive drug and will not undergo invasive treatment; the patients will receive elastic compression
Other: Elastic compression · Other: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
20 patients with varicose veins who will undergo invasive treatment (endovenous laser ablation with miniphlebectomy), followed by Venarus at a dosage of 1000 mg once daily for 6 months; the patients will also receive elastic compression
Drug: "Venarus®" (diosmin and hesperidin) · Procedure: Endovenous laser ablation (EVLA) with miniphlebectomy · Other: Elastic compression · Other: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
20 patients with varicose veins patients who will undergo invasive treatment (EVLK with miniphlebectomy), after which no venoactive drugs will be prescribed; the patients will also receive elastic compression
Procedure: Endovenous laser ablation (EVLA) with miniphlebectomy · Other: Elastic compression · Other: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
20 healthy volunteers without clinical and ultrasound signs of varicose veins receiving no treatment
Other: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
"Venarus®" (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months
Also known as: BIOFLAVANOIDS
Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.
All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment
The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment
changes in biomarkers of venous wall remodeling
Changes in biomarkers of venous wall remodeling including vimentin, fibronectin, PAI-1, vWF, CD31
Time frame: At baseline, and at 2, 3 and 6 months after the start of treatment
Changes in biomarkers expression in venous wall
Changes in expression of biomarkers of venous wall remodeling (vimentin, fibronectin, PAI-1, vWF, CD31) as assessed with Western blot techniques using the dilated veins harvested during miniphlebectomy
Time frame: 6 months
Started Apr 2023 (actual). Primary completion is estimated for Apr 2026, 36 months after the start.
Of 63 non-industry interventional studies with no phase under Varicose Veins, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 36 months is above that.
Counting every sponsor, half of 73 studies reached it within 22 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ryazan State Medical University